Abstract
Tyrosine kinase inhibitors (TKIs), particularly the combination of MEK inhibitors (cobimetinib and trametinib) and BRAF inhibitors
(vemurafenib and dabrafenib), are now considered as the first-line treatment of patients with BRAF V600-mutated metastatic
melanoma. Most cancer patients are on antidepressant drugs. In several case reports, vemurafenib has been reported for its adverse effects,
such as nephrotoxic and cardiotoxic effects, including QTc prolongation. The antidepressant drugs, such as escitalopram and mirtazapine are
also among the class of drugs that were reported to cause QTc prolongation and cardiac arrhythmias. This study is based on a patient with malignant
melanoma and the investigation on combination therapy of vemurafenib, cobimetinib, and concomitant antidepressant drugs (escitalopram
and mirtazapine). The patient had a history of recurrent syncope episodes, hypokalemia, QTc prolongation, and Torsades De Pointes
(TDP). The drug therapy was discontinued, and intracardiac defibrillator (ICD) was implanted for patient’s safety. Furthermore, QTc prolongation
and hypokalemia were persistent after drug discontinuation, indicating some degree of renal and/or cardiac injury. The patient was
discharged on beta-blocker and potassium replacement therapy.
Keywords:
Antidepressant drugs, cardiotoxicity, cobimetinib, malign melanoma, nephrotoxicity, and vemurafenib
References
1Negulescu M, Deilhes F, Sibaud V, et al. Panniculitis associated with MEK inhibitor therapy: an uncommon adverse effect. Case Rep Dermatol. 2017;9(1):80‐85.
2Fiocchi R, Gori M, Taddei F, Trevisani L, Gallo M, Eleftheriou G. Cardiac toxicity of combined vemurafenib and cobimetinib administration. Int J Clin Pharmacol Ther. 2019;57(5):259‐263.
3Kloth JSL, Pagani A, Verboom MC, et al. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer. 2015;112(6):1011‐1016.
4Launay-Vacher V, Zimner-Rapuch S, Poulalhon N, et al. Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients. Cancer. 2014;120(14):2158‐2163.
5Teuma C, Pelletier S, Amini-Adl M, et al. Adjunction of a MEK inhibitor to vemurafenib in the treatment of metastatic melanoma results in a 60% reduction of acute kidney injury. Cancer Chemother Pharmacol. 2017;79(5):1043‐1049.
6Lieu CH, Hidalgo M, Berlin JD, et al. A Phase Ib dose-escalation study of the safety, tolerability, and pharmacokinetics of cobimetinib and duligotuzumab in patients with previously treated locally advanced or metastatic cancers with mutant KRAS. Oncologist. 2017;22(9):1024‐e1089.
7Sala M, Coppa F, Cappucciati C, et al. Antidepressants: their effects on cardiac channels, QT prolongation and torsade de pointes. Curr Opin Investig Drugs. 2006;7(3):256‐263.
8Raftopoulos LG, Aggeli C, Zisimos K, et al. Cardiotoxicity after vemurafenib administration. Hellenic J Cardiol. 2019;60(4):256‐257.
9Jhaveri KD, Sakhiya V, Fishbane S. Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib. JAMA Oncol. 2015;1(8):1133‐1134.
10Cooke MJ, Waring WS. Citalopram and cardiac toxicity. Eur J Clin Pharmacol. 2013;69(4):755‐760.
11Goodnick PJ, Jerry J, Parra F. Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother. 2002;3(5):479‐498.
